Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy.
Bernardino Clavo, Daniel Ceballos, Dominga Gutierrez...
https://pubmed.ncbi.nlm.nih.gov/23102757/Actively Recruiting
Led by Bernardino Clavo, MD, PhD · Updated on 2026-09-18
42
Participants Needed
1
Research Sites
12 weeks
Total Duration
This clinical trial investigates the addition of rectal ozone therapy to the usual care for adults experiencing numbness and tingling caused by chemotherapy-induced peripheral neuropathy CIPN. The study aims to determine whether ozone therapy can improve patients self-reported symptoms and quality of life. The trial is a phase IIIII randomized, triple-blind study involving 42 adults with moderate or greater CIPN symptoms lasting at least three months. Participants will receive 40 sessions of rectal gas insufflation over 16 weeks, either with an ozoneoxygen gas mixture increasing concentration from 10 to 30 gmL or oxygen alone as a placebo. Both groups will continue their usual cancer and symptom treatments during the study. After treatment, participants will be followed for an additional 12 weeks to assess lasting effects. Throughout the 28-week study, participants will complete questionnaires about neuropathy, quality of life, anxiety, and depression. Researchers will also monitor biochemical markers of oxidative stress and inflammation, capture hyperspectral images of hands and feet, and assess treatment toxicity. These measures will help evaluate the impact and safety of ozone therapy compared to placebo.
CONDITIONS
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
B
Bernardino Clavo, MD, PhD
F
Francisco Rodríguez-Esparragón, BSc, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Bernardino Clavo, MD, PhD
Lead Sponsor
Council of Gran Canaria
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 16 weeks
Participants receive 40 sessions of rectal gas insufflation with either ozone/oxygen mixture or oxygen alone over 16 weeks, alongside their usual cancer symptom management.
2 to 3 sessions per week
Duration - 12 weeks
Participants are monitored for 12 weeks after treatment to assess changes in symptoms, quality of life, biochemical markers, and treatment safety.
Regular assessments and questionnaires
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Bernardino Clavo, Daniel Ceballos, Dominga Gutierrez...
https://pubmed.ncbi.nlm.nih.gov/23102757/Bernardino Clavo, Angeles Cánovas-Molina, Sara Cazorla-Rivero...
https://pubmed.ncbi.nlm.nih.gov/41572235/Bernardino Clavo, Francisco Rodríguez-Esparragón, Delvys Rodríguez-Abreu...
https://pubmed.ncbi.nlm.nih.gov/31779159/Renate Viebahn-Haensler, Olga Sonia León Fernández
https://pubmed.ncbi.nlm.nih.gov/34360655/Ellen M Lavoie Smith, Herbert Pang, Constance Cirrincione...
https://pubmed.ncbi.nlm.nih.gov/23549581/Bernardino Clavo, Angeles Cánovas-Molina, Yolanda Ramallo-Fariña...
https://pubmed.ncbi.nlm.nih.gov/36674232/Bernardino Clavo, Angeles Cánovas-Molina, Juan A Díaz-Garrido...
https://pubmed.ncbi.nlm.nih.gov/37599784/Francisco Javier Hidalgo-Tallón, Luis Miguel Torres-Morera, Jose Baeza-Noci...
https://pubmed.ncbi.nlm.nih.gov/35283802/Bernardino Clavo, Delvys Rodríguez-Abreu, Saray Galván...
https://pubmed.ncbi.nlm.nih.gov/36111149/Velio Bocci, Emma Borrelli, Valter Travagli...
https://pubmed.ncbi.nlm.nih.gov/19260079/Bernardino Clavo, MD, PhD
Lead Sponsor
Council of Gran Canaria
Collaborating Sponsor